在治疗牛皮的IL-23抑制剂治疗期间,具有免疫抑制微环境的EBV阳性霍奇金淋巴瘤
medRxiv : the preprint server for health sciences
|April 29, 2025
概括
这项研究详细介绍了第一个报告的埃普斯坦-巴尔病毒阳性经典霍奇金淋巴瘤 (EBV阳性cHL) 病例,该病例是在治疗牛皮后使用guselkumab治疗的. 由于IL-23抑制导致的免疫重编程可能导致了淋巴瘤.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
背景情况:
- 牛皮是一种炎症性皮肤疾病,通常用向疗法治疗.
- 干白素-23 (IL-23) 抑制剂在管理中度至重度牛皮方面是有效的.
- 免疫抑制疗法后二次恶性瘤的发展需要仔细监测.
研究的目的:
- 报告第一例发生在guselkumab治疗后的爱斯坦-巴尔病毒阳性经典霍奇金淋巴瘤 (EBV阳性cHL) 的病例.
- 为了研究瘤微环境和潜在的机制的潜在的淋巴发育.
- 探索IL-23抑制在免疫重编程中的作用及其与EBV阳性cHL的关联.
主要方法:
- 一个用guselkumab治疗的牛皮病患者的病例报告.
- 瘤微环境的高复合空间蛋白质组分析.
- 免疫细胞种群和细胞因子的分析.
主要成果:
- 患者在古塞尔库马布治疗后发展出EBV阳性cHL.
- 蛋白质组分析揭示了一个Th2极化,免疫抑制的瘤微环境.
- 有证据表明,由IL-23抑制驱动的免疫重编程.
结论:
- 对牛皮的古塞尔库马布治疗可能与EBV阳性cHL的风险增加有关.
- 抑制IL-23可以导致显著的免疫重编程,可能创造有利于淋巴瘤发展的环境.
- 需要进一步的研究来阐明精确的机制和长期风险.
更多相关视频
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
15.6K
10:31Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
Published on: April 8, 2016
14.5K
相关概念视频
01:24T Cell Types and Functions
615
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
615
01:27Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397